Image

Elon Musk took medication with Tesla board members: Report

Elon Musk’s use of unlawful medication was frequent information amongst a number of present and former Tesla Inc. and SpaceX administrators, the Wall Avenue Journal reported on Saturday.

There was concern concerning the quantity of Musk’s unlawful drug use and that he consumed medication with a few of his board members, the newspaper reported, citing individuals who have witnessed the drug use or have been briefed on it. The board didn’t maintain investigations on the problem, nor did it doc any issues, the paper mentioned.

The connection between Musk and his administrators was slammed by a Delaware decide this week, who cited the board’s conflicts of curiosity in her ruling that Musk’s $55 billion pay bundle was extreme.

Musk and his lawyer, Alex Spiro, didn’t reply to the WSJ’s requests for remark. The paper beforehand reported that Musk has used LSD, cocaine, ecstasy and psychedelic mushrooms, usually at non-public events. Spiro informed the WSJ in that report that Musk was recurrently and randomly drug examined at SpaceX and had by no means failed a check.

Some buddies and administrators felt they they needed to take unlawful medication with Musk because it might in any other case upset him, the paper reported Saturday, citing a number of the individuals. In addition they didn’t wish to threat “losing the social capital” of being in his circle, the paper mentioned.

Musk responded on X to the WSJ story final month about his alleged drug use.

“Whatever I’m doing, I should obviously keep doing it!” Musk posted on X, citing Tesla and SpaceX as being the world’s most respected automotive and house corporations. “If drugs actually helped improve my net productivity over time, I would definitely take them!”

Musk oversees six corporations: Tesla, SpaceX and X, the social media firm previously often called Twitter; the tunneling enterprise The Boring Co.; mind implant developer Neuralink; and synthetic intelligence startup xAI.

Subscribe to the Eye on AI e-newsletter to remain abreast of how AI is shaping the way forward for enterprise. Sign up at no cost.

SHARE THIS POST